Inhibition of neutral endopeptidase by thiorphan does not modify coronary vascular responses to angiotensin I, angiotensin II and bradykinin in the isolated guinea pig heart

Pharmacological Reports

Volumn 59, Issue 4, 2007, Pages 421-427

  Kozlovski, Valery I ^a,b   Lomnicka, Magdalena ^a   Jakubowski, Andrzej ^a   Chlopicki, Stefan ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b GRODNO STATE MEDICAL UNIVERSITY   (Belarus)

Author keywords

Angiotensin; Angiotensin converting enzyme; Coronary vessels; Guinea pig heart; Neutral endopeptidase

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; MEMBRANE METALLOENDOPEPTIDASE; PERINDOPRILAT; THIORPHAN;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; GUINEA PIG; ISOLATED HEART; NONHUMAN;

EID: 35048847901     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ahmad M, Zeitlin IJ, Parratt JR, Pitt AR: Degradation of bradykinin, a cardioprotective substance, during a single passage through isolated rat-heart. Arch Pharm. Res, 2006, 29, 241-248.
2. Bartus JB, Chlopicki S: Effect of neutral endopeptidase inhibition on vascular response induced by exogenous angiotensin I in the isolated rat lung. Pol J Pharmacol, 2003, 55, 1071-1078.
3. Campbell DJ: Vasopeptidase inhibition: a double-edged sword? Hypertension, 2003, 41, 383-389.
4. Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA: Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther, 1998, 287, 567-577.
5. Chen HH, Burnett JC Jr.: C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol, 1998, 32, Suppl 3, S22-S28.
6. Corti R, Burnett JC Jr., Rouleau JL, Ruschitzka F, Luscher TF: Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation, 2001, 104, 1856-1862.
7. Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE: Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension, 2004, 44, 913-918.
8. Deddish PA, Marcic BM, Tan F, Jackman HL, Chen Z, Erdos EG: Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor. Hypertension, 2002, 39, 619-623.
9. Dumoulin MJ, Adam A, Rouleau JL, Gosselin H, Lamontagne D: Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction. Can J Physiol Pharmacol, 2003, 81, 740-746.
10. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI: Counterregulatory actions of angiotensin-(1-7). Hypertension, 1997, 30, 535-541.
11. Ferro CJ, Spratt JC, Haynes WG, Webb DJ: Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation, 1998, 97, 2323-2330.
12. Gafford JT, Skidgel RA, Erdos EG, Hersh LB: Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry, 1983, 22, 3265-3271.
13. Graf K, Grafe M, Auch-Schwelk W, Baumgarten CR, Bossaller C, Fleck E: Bradykinin degrading activity in cultured human endothelial cells. J Cardiovasc Pharmacol, 1992, 20, Suppl 9, S16-S20.
14. Kentsch M, Otter W, Drummer C, Notges A, Gerzer R, Multer-Esch G: Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol, 1996, 51, 269-272.
15. Kerth PA, Vanhoutte PM: Effects of perindoprilat on endothelium-dependent relaxations and contractions in isolated blood vessels. Am J Hypertens, 1991, 4, 226S-234S.
16. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E: Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens, 2004, 17, 103-111.
17. Kozlovski VI, Lomnicka M, Chlopicki S: Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol Rep, 2006, 58, Suppl, 103-110.
18. Kozlovski VI, Olszanecki R, Chlopicki S: Free radicals generated by xanthine/xanthine oxidase system augment nitric oxide synthase (NOS) and cyclooxygenase (COX)-independent component of bradykinin-induced vasodilatation in the isolated guinea pig head. Pharmacol Rep, 2006, 58, 405-412.
19. Krassoi I, Pataricza. J, Papp JG: Thiorphan enhances bradykinin-induced vascular relaxation in hypoxic/hyperkalaemic porcine coronary artery. J Pharm Pharmacol, 2003, 55, 339-345.
20. Llorens-Cortes C, Huang H, Vicart P, Gasc JM, Paulin D, Corvol P: Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins. J Biol Chem, 1992, 267, 14012-14018.
21. Marton Z, Pataricza, J, Krassoi I, Varro A, Papp JG: NEP inhibitors enhance C-type natriuretic peptide-induced relaxation in porcine isolated coronary artery. Vascul Pharmacol, 2005, 43, 207-212.
22. Miyamoto A, Murata S, Nishio A: Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery. Naunyn Schmiedebergs Arch Pharmacol, 2002, 365, 365-370.
23. Nakano A, Miura T, Miki T, Nozawa Y, Ichikawa Y, Ura N, Shimamoto K: Effects of neutral endopeptidase 24.11 inhibitionpn myocardial infarct size and ischemic preconditioning in rabbits. Naunyn Schmiedebergs Arch Pharmacol, 2002, 366, 335-342.
24. Oliveri C, Ocaranza MP, Campos X, Lavandero S, Jalil JE: Angiotensin I-converting enzyme modulates. neutral endopeptidase activity in the rat. Hypertension, 2001, 38, 650-654.
25. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation, 2002, 106, 920-926.
26. Pu Q, Amiri F, Gannon P, Schiffrin EL: Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypestensive rats. J Hypertens, 2005, 23, 401-409.
27. Ramirez-Molina C, Heudi O, Pullen M, Marshall PS: Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. J Pept Sci, 2006, 12, 220-226.
28. Richards AM: Thd renin-angiotensin-aldosterone system and the cardiac natriuretic peptides. Heart, 1996, 76, 36-44.
29. Richards M, Espiner E, Frampton C et al.: Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension, 1990, 16, 269-276.
30. Rougeot C, Messaoudi M, Hermitte V, Rigault AG, Blisnick T, Dugave C, Desor D, Rougeon F: Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity. Proc Natl Acad Sci USA, 2003, 100, 8549-8554.
31. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kend EK, Porter CB et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet, 2000, 356, 615-620.
32. Russell JC, Kelly SE, Schafer S: Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat. J Cardiovasc Pharmacol, 2004, 44, 258-265.
33. Scholkens BA, Linz W: Local inhibition of angiotensin II formation and bradykinin degradation in isolated hearts. Clin Exp Hypertens A, 1988, 10, 1259-1270.
34. Sibinga NE, Ware JA: A pair of ACEs, for openers? Circ Res, 2000, 87, 523-525.
35. Tom B, Dendorfer A, de VR, Saxena PR, Jan Danser AM Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol, 2002, 137, 276-284.
36. Auch-Schwelk W, Bossaller C, Claus M, Graf K, Grafe M, Fleck E: Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries. J Cardiovasc Pharmacol, 1992, 20, Suppl 9, S62-S67.
37. Weckler N, Leitzbach D, Kalinowski L, Malinski T, Busch AE, Linz W: Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits. J Renin Angiotensin Aldosterone Syst, 2003, 4, 191-196.
38. Xiang JZ, Linz W, Becker H, Ganten D, Lang RE, Schölkens B, Unger T: Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. Eur J Pharmacol, 1985, 113, 215-223.
39. Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja-Tebbe N, Yang XP: Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail, 2004, 10, 83-89.
40. Yamamoto A, Keil LC, Reid IA: Effect of intrarenal bradykinin infusion on vasopressin release in rabbits. Hypertension, 1992, 19, 799-803.
41. Zhang X, Nasjletti A, Xu X, Hintze TH: Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism. J Cardiovasc Pharmacol, 1998, 31, 623-629.
42. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC: Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation, 2003, 108, 1707-1712.